ArticleClinical transplantation and research2025
Tailored strategies for emergency ABO-incompatible living donor liver transplantation: a series of three cases.
Article in Clinical transplantation and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ABO-incompatible (ABOi) living donor liver transplantation (LDLT) carries a substantial risk of antibody-mediated rejection (AMR) in both the short and long term. However, when no ABO-compatible donor is available, ABOi LDLT can be a viable option for patients with liver failure requiring emergency transplantation. To prevent AMR, various strategies have been implemented. However, typically, a pretransplant preparation period of at least 2 to 3 weeks is required to reduce the CD19+ or CD20+ cell count and antibody levels to an acceptable threshold (1:64). In emergency ABOi cases, due to time constraints, the desensitization protocol must be modified in accordance with the patient's needs. We present a series of three cases involving emergency ABOi LDLT: one of primary graft nonfunction and two of acute-on-chronic liver failure. The goal was to achieve both short- and long-term rejection-free outcomes. Each case required different protocols based on the patient's antibody titer, clinical condition, and intraoperative findings, and postoperative immunosuppression regimens were also individualized according to each patient's clinical condition. This case series demonstrates the safety and feasibility of emergency ABOi LDLT with modifications to the desensitization protocol. However, further research into emergency ABOi transplantation is necessary to establish recommendations for managing such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.